| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K96431673 | CTRPv2 | pan-cancer | AAC | -0.045 | 0.6 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.031 | 0.6 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | procarbazine | CTRPv2 | pan-cancer | AAC | 0.023 | 0.6 |
| mRNA | RAF265 | FIMM | pan-cancer | AAC | -0.11 | 0.6 |
| mRNA | BRD-K48334597 | CTRPv2 | pan-cancer | AAC | 0.041 | 0.6 |
| mRNA | thapsigargin | gCSI | pan-cancer | AAC | -0.033 | 0.6 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.027 | 0.6 |
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | 0.024 | 0.6 |
| mRNA | lapatinib | FIMM | pan-cancer | AAC | 0.1 | 0.6 |